Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2010; postbronchodilator FEV1/FVC \< 70%, and postbronchodilator FEV1 ≥ 30% and \< 80% predicted
Current or former cigarette smokers
You may not be if
Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit
Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1
Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness
History or presence of asthma verified from medical records
Chronic use of oxygen therapy greater than or equal to 15 hours per day
Patient with uncontrolled infection due to HIV and/or active hepatitis
Patients with a history of hypersensitivity reaction to inhaled anticholinergics
Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.
Clareo Health | Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)
